OBIO vs. DCTH, BFLY, RXST, CARL, NPCE, DRTS, CLPT, SNWV, SMTI, and TCMD
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Delcath Systems (DCTH), Butterfly Network (BFLY), RxSight (RXST), Carlsmed (CARL), NeuroPace (NPCE), Alpha Tau Medical (DRTS), ClearPoint Neuro (CLPT), Sanuwave Health (SNWV), Sanara MedTech (SMTI), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Orchestra BioMed (NASDAQ:OBIO) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
Delcath Systems has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Delcath Systems has a net margin of 3.18% compared to Orchestra BioMed's net margin of -2,367.49%. Delcath Systems' return on equity of 6.91% beat Orchestra BioMed's return on equity.
53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by insiders. Comparatively, 17.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Orchestra BioMed had 9 more articles in the media than Delcath Systems. MarketBeat recorded 12 mentions for Orchestra BioMed and 3 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.78 beat Orchestra BioMed's score of 0.90 indicating that Delcath Systems is being referred to more favorably in the news media.
Orchestra BioMed currently has a consensus target price of $13.50, indicating a potential upside of 425.29%. Delcath Systems has a consensus target price of $24.50, indicating a potential upside of 126.01%. Given Orchestra BioMed's higher probable upside, equities analysts plainly believe Orchestra BioMed is more favorable than Delcath Systems.
Orchestra BioMed has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
Summary
Delcath Systems beats Orchestra BioMed on 12 of the 16 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 9/13/2025 by MarketBeat.com Staff
Free OBIO Stock Alerts